Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TECOS cardiovascular outcomes trial of sitagliptin in type 2 diabetes
NL-OMON39187Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin + usual care with Placebo + usual care (2 arms). Primary endpoint: Primary cardiovascular composite endpoint. Started Dec 2009; status: active, not recruiting.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON39187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39187.